Geode Capital Management, LLC Rhythm Pharmaceuticals, Inc. Transaction History

Geode Capital Management, LLC

$1.21 Trillion
Q3 2024

A detailed history of Geode Capital Management, LLC transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,256,188 shares of RYTM stock, worth $77.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,256,188

Previous 1,252,689 0.28%

Holding current value

$77.9 Million

Previous $51.4 Million 27.95%

% of portfolio

0.01%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$40.81 - $55.0 $142,794 - $192,445	3,499 Added 0.28%	1,256,188 $65.8 Million
Q2 2024 Aug 09, 2024	BUY	$35.41 - $44.37 $2.55 Million - $3.19 Million	71,984 Added 6.1%	1,252,689 $51.4 Million
Q1 2024 May 13, 2024	BUY	$39.12 - $52.44 $2.41 Million - $3.23 Million	61,576 Added 5.5%	1,180,705 $51.2 Million
Q4 2023 Feb 13, 2024	BUY	$21.39 - $49.64 $1.58 Million - $3.68 Million	74,072 Added 7.09%	1,119,129 $51.4 Million
Q3 2023 Nov 13, 2023	BUY	$15.81 - $27.8 $1.13 Million - $1.99 Million	71,707 Added 7.37%	1,045,057 $24 Million
Q2 2023 Aug 11, 2023	BUY	$16.32 - $21.15 $8.17 Million - $10.6 Million	500,589 Added 105.89%	973,350 $16.1 Million
Q1 2023 May 15, 2023	BUY	$16.88 - $34.24 $240,556 - $487,954	14,251 Added 3.11%	472,761 $8.43 Million
Q4 2022 Feb 13, 2023	BUY	$22.21 - $30.25 $1.56 Million - $2.13 Million	70,398 Added 18.14%	458,510 $13.4 Million
Q3 2022 Nov 14, 2022	SELL	$4.3 - $30.85 $50,232 - $360,389	-11,682 Reduced 2.92%	388,112 $9.51 Million
Q2 2022 Aug 12, 2022	SELL	$3.12 - $12.25 $1.06 Million - $4.18 Million	-341,095 Reduced 46.04%	399,794 $1.66 Million
Q1 2022 May 13, 2022	BUY	$6.13 - $12.24 $164,657 - $328,778	26,861 Added 3.76%	740,889 $8.54 Million
Q4 2021 Feb 11, 2022	BUY	$8.62 - $13.9 $399,709 - $644,543	46,370 Added 6.95%	714,028 $7.13 Million
Q3 2021 Nov 12, 2021	SELL	$11.68 - $20.72 $201,421 - $357,316	-17,245 Reduced 2.52%	667,658 $8.72 Million
Q2 2021 Aug 13, 2021	BUY	$18.52 - $22.55 $1.14 Million - $1.38 Million	61,341 Added 9.84%	684,903 $13.4 Million
Q1 2021 May 12, 2021	BUY	$20.25 - $39.49 $2.74 Million - $5.34 Million	135,115 Added 27.66%	623,562 $13.3 Million
Q4 2020 Feb 12, 2021	SELL	$21.17 - $32.61 $68,421 - $105,395	-3,232 Reduced 0.66%	488,447 $14.5 Million
Q3 2020 Nov 13, 2020	BUY	$18.13 - $30.61 $270,662 - $456,976	14,929 Added 3.13%	491,679 $10.7 Million
Q2 2020 Aug 13, 2020	BUY	$14.41 - $25.35 $482,634 - $849,047	33,493 Added 7.56%	476,750 $10.6 Million
Q1 2020 May 14, 2020	BUY	$13.16 - $22.9 $597,227 - $1.04 Million	45,382 Added 11.41%	443,257 $6.75 Million
Q4 2019 Feb 13, 2020	BUY	$19.53 - $25.5 $1.57 Million - $2.06 Million	80,602 Added 25.4%	397,875 $9.14 Million
Q3 2019 Nov 12, 2019	BUY	$18.62 - $24.51 $88,202 - $116,103	4,737 Added 1.52%	317,273 $6.85 Million
Q2 2019 Aug 14, 2019	BUY	$21.11 - $28.48 $1.28 Million - $1.72 Million	60,519 Added 24.01%	312,536 $6.88 Million
Q1 2019 May 14, 2019	BUY	$24.76 - $31.66 $448,725 - $573,774	18,123 Added 7.75%	252,017 $6.91 Million
Q4 2018 Feb 13, 2019	BUY	$24.11 - $31.34 $1.31 Million - $1.7 Million	54,247 Added 30.2%	233,894 $6.29 Million
Q3 2018 Nov 13, 2018	BUY	$26.99 - $35.85 $2.4 Million - $3.18 Million	88,819 Added 97.79%	179,647 $5.24 Million
Q2 2018 Aug 14, 2018	SELL	$17.02 - $35.2 $485,580 - $1 Million	-28,530 Reduced 23.9%	90,828 $2.84 Million
Q1 2018 May 15, 2018	SELL	$19.9 - $32.25 $88,296 - $143,093	-4,437 Reduced 3.58%	119,358 $2.38 Million
Q4 2017 Feb 13, 2018	BUY	$22.0 - $30.51 $2.72 Million - $3.78 Million	123,795	123,795 $3.6 Million

Others Institutions Holding RYTM

# of Institutions

192

Shares Held

67.3M

Call Options Held

834K

Put Options Held

78.6K

View Full List

About RHYTHM PHARMACEUTICALS, INC.

Ticker RYTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,720,000
Market Cap $3.46B
Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...

More about RYTM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Rhythm Pharmaceuticals, Inc. Transaction History